论文部分内容阅读
促甲状腺激素(TSH)抑制治疗是否会对骨密度造成影响,导致部分分化型甲状腺癌(DTC)患者出现骨质疏松症状?尚存争议.笔者从基础实验与临床研究的角度,综述DTC的TSH抑制治疗中骨代谢变化的研究现状.“,”Whether thyroid-stimulating hormone (TSH) suppression therapy may change bone mineral density and cause osteoporosis signs in some patients with differentiated thyroid carcinoma (DTC) remains controversial. Here, the authors present the current research progress of DTC TSH suppression therapy associated changes in bone metabolism from the viewpoints of both experimental and clinical studies.